Peripheral Manifestations in Spondyloarthritis and their Effect: An Ancillary Analysis of the ASAS-COMOSPA Study

Objective.To determine the factors associated with the presence of peripheral manifestations in patients with spondyloarthritis (SpA) from the Assessment in SpondyloArthritis international Society (ASAS)-COMOSPA study, and to evaluate the effect of these symptoms on treatment and patient-reported outcomes (PRO).Methods.All patients from the ASAS-COMOSPA study were included. All patients had an SpA diagnosis according to the rheumatologist. Patients and disease characteristics associated with the presence of these peripheral manifestations (peripheral arthritis, peripheral enthesitis, or dactylitis) were analyzed by univariate and multivariate logistic regression. Patients who reported peripheral manifestations were divided into 3 categories: current, history, and no history. The effect of peripheral involvement on PRO was evaluated through the use of 1-factor ANOVA.Results.Out of the 3984 patients included in ASAS-COMOSPA, 2562 (64.3%) reported at least 1 peripheral manifestation, with a prevalence of 51.5%, 37.8%, and 15.6% for peripheral arthritis, peripheral enthesitis, and dactylitis, respectively. Being from South America, having a history of uveitis, having a current case or history of psoriasis, and the absence of HLA-B27 were associated with higher prevalence of peripheral manifestations. Patients with peripheral involvement showed greater use of drugs, and those with “current” peripheral manifestations showed higher levels in all PRO, in contrast to those with past or no history.Conclusion.Peripheral manifestations appear in 64% of patients with SpA. Psoriasis and the absence of HLA-B27 are associated with the development of peripheral symptoms. The presence of any peripheral symptom at the time of the visit was associated with higher scores in all PRO.

Download Full-text

Assessing the change in disease severity based on depressive symptoms in real-world psoriasis patients

Journal of Comparative Effectiveness Research ◽

10.2217/cer-2021-0106 ◽

2021 ◽

Author(s):

Neda Shahriari ◽

Sarah Mattessich ◽

Tin-Chi Lin ◽

Heather J Litman ◽

Robert R McLean ◽

...

Keyword(s):

Depressive Symptoms ◽

Patient Reported Outcomes ◽

Systemic Treatment ◽

Disease Characteristics ◽

Significant Difference ◽

Patient Reported ◽

History Of ◽

Baseline Characteristics ◽

History Of Depression ◽

Systemic Therapies

Aim: To evaluate whether the presence of a history of depression hinders psoriasis response to systemic therapies and to delineate baseline characteristics of patients whose depressive symptoms improved on systemic treatment. Methods: We studied patients within the Corrona® Psoriasis Registry, a prospective, multicenter observational disease-based registry, that were enrolled through September 2018, comparing changes from enrollment to 12-month visit. Results: There was a statistically significant improvement in all disease characteristics and most patient-reported outcomes in patients reporting a history of depression and in those that did not while there was no statistically significant difference in the degree of change comparing these two cohorts. Patients who noted improvement in depressive symptoms had more severe baseline disease characteristics and reported overall worse baseline patient-reported outcomes. Conclusions: History of depression does not portend a differential response to systemic treatment. Patients with improvement in depressive symptoms had worse baseline characteristics.

Download Full-text

Patient-reported outcomes across cerebrovascular event types

Neurology ◽

10.1212/wnl.0000000000006626 ◽

2018 ◽

Vol 91 (23) ◽

pp. e2182-e2191 ◽

Cited By ~ 10

Author(s):

Irene L. Katzan ◽

Andrew Schuster ◽

Christopher Newey ◽

Ken Uchino ◽

Brittany Lapin

Keyword(s):

Ischemic Stroke ◽

Executive Function ◽

Physical Function ◽

Patient Reported Outcomes ◽

Social Roles ◽

Factors Associated ◽

Cerebrovascular Events ◽

Patient Reported ◽

Health Domains ◽

Domain Scores

ObjectivesTo compare the degrees to which 8 domains of health are affected across types of cerebrovascular events and to identify factors associated with domain scores in different event types.MethodsThis was an observational cohort study of 2,181 patients with ischemic stroke, intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), or TIA in a cerebrovascular clinic from February 17, 2015, to June 2, 2017 who completed Quality of Life in Neurologic Disorders executive function and the following Patient-Reported Outcomes Measurement Information System scales as part of routine care: physical function, satisfaction with social roles, fatigue, anxiety, depression, pain interference, and sleep disturbance.ResultsAll health domains were affected to similar degrees in patients with ICH, SAH, and ischemic stroke after adjustment for disability and other clinical factors, whereas patients with TIA had worse adjusted scores for 5 of the 8 domains of health. Female sex, younger age, lower income, and event <90 days were associated with worse scores in multiple domains. Factors associated with health domain scores were similar for all cerebrovascular events. Most affected domains for all were physical function, satisfaction with social roles, and executive function.ConclusionsThe subtype of stroke (ischemic stroke, ICH, and SAH) had similar effects in multiple health domains, while patients with TIA had worse adjusted outcomes, suggesting that the mechanisms for outcomes after TIA may differ from those of other cerebrovascular events. The most affected domains across all event types were physical function, satisfaction with social roles, and executive function, highlighting the need to develop effective interventions to improve these health domains in survivors of these cerebrovascular events.

Download Full-text

Disease characteristics and patient reported outcomes in psoriasis patients treated with secukinumab in a real world setting: Results from the Corrona Psoriasis Registry

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2017.04.409 ◽

2017 ◽

Vol 76 (6) ◽

pp. AB102

Keyword(s):

Real World ◽

Patient Reported Outcomes ◽

Disease Characteristics ◽

Real World Setting ◽

Patient Reported

Download Full-text

Quality of life and mental health in breast cancer survivors compared with non-cancer controls: a study of patient-reported outcomes in the United Kingdom

Journal of Cancer Survivorship ◽

10.1007/s11764-020-00950-3 ◽

2020 ◽

Author(s):

Helena Carreira ◽

Rachael Williams ◽

Harley Dempsey ◽

Susannah Stanway ◽

Liam Smeeth ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Primary Care ◽

Cancer Survivors ◽

Patient Reported Outcomes ◽

Breast Cancer Survivors ◽

Patient Reported ◽

History Of ◽

History Of Cancer

Abstract Purpose There is limited high-quality evidence on quality of life, anxiety, and depressive symptoms in breast cancer survivors and women with no history of cancer. We aimed to address this by comparing patient-reported outcomes between breast cancer survivors and women with no history of breast cancer. Methods Breast cancer survivors and women with no prior cancer were selected from the UK Clinical Practice Research Datalink GOLD primary care database, which includes population-based primary care electronic health record data. Breast cancer survivors and controls were frequency matched by age and primary care practice. Outcomes were assessed with validated instruments via postal questionnaire. Linear and logistic regression models were fitted to estimate adjusted associations between breast cancer survivorship and outcomes. Results A total of 356 breast cancer survivors (8.1 years post diagnosis) and 252 women with no prior cancer participated in the study. Compared with non-cancer controls, breast cancer survivors had poorer QoL in the domains of cognitive problems (adjusted β (aβ) = 1.4, p = 0.01), sexual function (aβ = 1.7, p = 0.02) and fatigue (aβ = 1.3, p = 0.01), but no difference in negative feelings, positive feelings, pain, or social avoidance. Breast cancer survivors had higher odds of borderline-probable anxiety (score ≥ 8) (adjusted OR = 1.47, 95%CI:1.15–1.87), but no differences in depression. Advanced stage at diagnosis and chemotherapy treatment were associated with poorer QoL. Conclusions Compared with women with no history of cancer, breast cancer survivors report more problems with cognition, sexual function, fatigue, and anxiety, particularly where their cancer was advanced and/or treated with chemotherapy. Implications for Cancer Survivors Breast cancer survivors with more advanced disease and/or treated with chemotherapy should be closely monitored and, when possible, offered evidence-based intervention for fatigue, cognitive dysfunction, and sexual problems.

Download Full-text